الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 116 |  |  |
| | | from | 116 | | |
Abstract
The Federal Drug Administration approved the first commercially available statin, lovastatin, in 1987. About thirty years later, statins are unquestionably regarded as a (if not THE) pillar in the prevention and treatment of cardiovascular disease (CVD). Statins reduce low-density lipoprotein cholesterol levels by 25–50%, depending on the dosage. As a result, total and CVD mortality, cardiac and cerebrovascular events rates are reduced by 25–40%. These positive effects, like all drugs, can be followed by negative effects in certain patients. In a condition known as ”statin sensitivity,” these unwelcome symptoms may vary from mild, self-limiting effects on more severe symptoms that contribute to the discontinuation of statin therapy. Statin-associated muscle symptoms (SAMS) are the most frequently recorded side effect, and myalgia can occur in up to 20%–29% of statin-treated patients. There is currently insufficient evidence to definitively determine whether vitamin D plasma concentrations affect the frequency and severity of SAMS. Our research looked at the relationship between vitamin D blood levels and statin-associated muscle symptoms (SAMS), and it included 60 patients on statin therapy and 25 healthy controls who visited Mansura University outpatient clinics. Serum vitamin D, lipid profile, CPK, and CRP were obtained from the participants, and needle EMG was performed on the symptomatic patients. We have summarized evidence suggesting that • Low concentrations of vitamin D were significantly associated with development of statin associated muscle symptoms (SAMS). • Vitamin D deficiency neither related to statin dose nor duration. • The levels of lipid profile of SAMS patients group are strongly associated with decrease vitamin D level. • Levels of CPK were correlated to vitamin D deficiency in SAMS patient group and Needle EMG study confirmed the diagnosis in most patients. According to these data, we conclude that: Our study supporting the hypothesis who suggested that, the vitamin D blood level and statin associated muscle symptom (SAMS) are realated to each other.